Company intelligence / Profile preview

Enviro Therapeutics, Inc.

Los Angeles/Southern CA area, California, United Stateskairospharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Enviro Therapeutics developed immune-based therapeutics targeting resistance and immune suppression in oncology. Its lead asset, ENV105/Carotuximab, is in Phase II trials for prostate cancer and Phase I for non-small cell lung cancer. Early data suggest promising response rates in heavily pretreated prostate cancer patients. The broader portfolio includes seven drug candidates at various stages.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesSmall moleculesAutologous T cell therapy
Industry: Biotech

Drug pipeline

4 assets

ENV105

Phase 2

Indications: Prostate cancer, Non-small cell lung cancer

3 more assets in the full pipeline.

Request access →

Partnerships

Cedars-Sinai Medical Center (technology licensing partner)

Beyond the preview

Go deeper on Enviro Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enviro Therapeutics, Inc..

Explore the full profile